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Background: Reperfusion injury in the myocardium has recently been consid- 
ered to be a type of inflammation, and close attention has been paid to the 
possible involvement ofneutrophils, complement, and cytokines in the onset of 
this injury. Recently, it has been reported that serum levels of interleukin-6 are 
elevated significantly after myocardial infarction. The major site of interleu- 
kin-6 production and its exact roles are still unknown. In this study, we 
hypothesized that myocytes may produce interleukinl6 during hypoxia nd this 
may play a role in neutrophil-mediated reperfusion injury. Methods and results: 
In the clinical study, 20 patients who underwent coronary artery bypass 
grafting were divided into 2 groups: group F, in which patients were treated 
with a serine protease inhibitor (FUT-175, 2 mg/kg per hour) during cardio- 
pulmonary bypass, and group C (untreated patients). In group C, myocardial 
interleukin-6 production, as determined by the difference between the inter- 
leukin-6 level in the cardiopuimonary b pass circuit and its level in coronary 
venous blood, increased significantly after reperfusion (12 -- 4 pg/mL) as 
compared with that before aortic crossclamping (2 - 2 pg/mL). In group F, the 
increase in the interleukin-6 level was suppressed significantly (before aortic 
crossclamping, 3 ± 2 pg/mL; after reperfusion, 4 ± 3 pg/mL). The interleu- 
kin-6 production differed significantly between group C and group F. In the in 
vitro experimental study, the supernatant from myocytes exposed to 2 hours of 
hypoxia (group 2H) showed significantly higher levels of interleukin-6 (455 ± 
260 pg/mL) than that from normoxic myocytes (group N) (47 ± 15 pg/mL). 
This intedeukin-6 production wassuppressed by the addition of FUT-175 
(123 ± 24 pg/mL). The interleukin-6 production by endothelial cells of 
coronary vessels did not differ between group 2H (283 -+ 151 pg/mL) and group 
N (151 ± 86 pg/mL). In a coincubation system with a monolayer of endothelial 
cells on collagen membrane and myocytes under collagen membrane in a 
modified Boyden chamber, 2 hours of coincubation showed a significantly 
higher percent of neutrophil transendotheliai m gration (group 2H vs N, 78% 
± 13% vs 26% ± 11%), value of chemiluminescence (22- 8 vs 5 ± 2 x 103 
counts/3 minutes), and percent of irreversibly damaged myocytes (48% ± 17% 
vs 12% ± 8%) than normoxic oincubation. In contrast, anti-interleukin-6 
monoclonal ntibody significantly attenuated neutrophil transendothelial mi- 
gration (42% ± 19%) and irreversible damage of myocytes (26% + 15%) in 2 
hours of coincubation. Conclusions: Interleukin-6 is produced from myocar- 
dium during ischemia nd reperfusion i patients undergoing coronary bypass 
grafting. This interleukin-6 may be derived from hypoxic myocytes and play a 
role in neutrophil-mediated reperfusion injury in myocardium. (J Thorac 
Cardiovasc Surg 1998;116:511-7) 
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I nflammatory response has recently been consid- ered to be involved in a mechanism of postisch- 
emic reperfusion injury in myocardium, and close 
attention has been paid to the possible involvement 
of ncutrophils, complement, and cytokines in the 
onset of this injury] -(' We previously suggested the 
involvement of neutrophils in this injury, on the 
grounds that myocardial reperfusion injury during 
surgery was reduced by reperfusion with leukocyte- 
depleted blood, 4-6 by the use of cyclic adenosine 
monophosphate phosphodiesterase inhibitor, which 
inhibits leukocyte aggregation, 7 and by the use of 
Na+/H + exchanger inhibitors, s We have also re- 
ported that ischemic cardiac myocytes produced 
signaling factors, resulting in enhancement of neu- 
trophil migration into the injured area and aggrava- 
tion of myocardial injury. 9 However, such a myo- 
cyte-derived factor that promotes the neutrophil- 
mediated reperfusion injury has not yet been 
comprehensively studied. 
Meanwhile, it has been reported that serum levels 
of cytokines in blood, especially that of interleukin-6 
(IL-6), are elevated significantly after myocardial 
infarction 1°'~ and that IL-6 messenger RNA 
(mRNA) is expressed in infarct myocardium 12or 
hypoxic neonatal myocytes. 13 Thus the possible in- 
volvement of IL-6, an inflammation-related cyto- 
kine, in myocardial reperfusion injury has been 
attracting attention. We previously reported that 
although extracorporeal circulation induces inflam- 
matory reactions and elevates the levels of inflam- 
matory cytokines uch as IL-6 and IL-8, these reac- 
tions are suppressed by a serine protease inhibitor 
nafamostat mesylate (FUT-175, Torii Pharmaceuti- 
cal Company, Tokyo, Japan), possibly leading to 
reduced myocardial injury. 14 It therefore seems 
likely that IL-6 may be produced possibly via inflam- 
matory response including a protease-mediated 
pathway from myocardium during postischemic 
reperfusion in patients undergoing coronary artery 
bypass grafting (CABG) and that it is responsible 
for exacerbation of neutrophil-rnediated myocardial 
injury. However, the major site of IL-6 production in 
the human myocardium and its exact roles are still 
unknown. 
We recently carried out a clinical study in which 
IL-6 levels in coronary venous blood were mea- 
sured in patients undergoing CABG. At the same 
time, we performed an experiment in vitro to 
examine whether IL-6 was produccd possibly via a 
protease-mediated pathway by hypoxic cardiac 
myocytes and whether this might be responsible 
for neutrophi l -mediated myocardial reperfusion 
injury. 
Patients and methods 
Clinical study. The subjects of the clinical study were 
20 patients who underwent CABG in 1994 at the First 
Department of Surgery, Osaka University Hospital. In- 
formed consent according to the Institutional Review 
Board in Osaka University was obtained fro m all patients. 
Neither the patient nor the surgeon was informed of the 
group in which that patient was involved, but the investi- 
gators were not blinded. Patients were randomly divided 
into 2 groups: group F (patients treated with FUT-175) 
and group C (untreated patients). Conventional cold 
blood cardioplegic solution (15 ° C) containing only potas- 
sium (16 mEq/L) was used for myocardial protection. It
was antegradely administered ata rate of 10 mL/kg, and 
then half its volume was administered retrogradely every 
20 minutes. Its myocardial temperature was kept below 
20 ° C. In all patients, membrane oxygenators (Capiox, 
Terumo, Tokyo, Japan) were used and the temperature of 
the cardiopulmonary b pass (CPB) circuit was maintained 
at 34 ° C as a tepid CPB. 
In all group F patients, FUT-175 was administered into 
the CPB circuit at a rate of 2 mg/kg per hour during CPB 
for about 130 minutes (132 _+_ 36 minutes). FUT-175 is an 
inhibitor of serine protease, attenuates the inflammatory 
response, and has no side effect when used at a dose less 
than 2 mg/kg per hour for human beings. TM The patients 
were administered neither anti-inflammatory drugs nor 
antifibrinolytic drugs. Four patients in group F and 5 
patients in group C received a transfusion after CPB, but 
no patient received one during CPB. 
The mean age was 63 _+ 18 years in group C and 61 _+ 
16 years in group F. The number of grafts averaged 2.8 _+ 
0.4 in group C and 2.6 _+ 0.6 in group F. The duration of 
aortic crossclamping averaged 95 + 45 minutes in group C 
and 88 -+ 26 minutes in group F. The duration of CPB 
averaged 132 -+ 36 minutes in group C and 119 + 29 
minutes in group F. None of these parameters differed 
significantly between the 2 groups (Table I). The postop- 
erative course was uneventful in all cases. 
In both groups, coronary sinus blood (CS) and arterial 
blood in the CPB circuit (A) were sampled before aortic 
crossclamping and 10 minutes after reperfusion. The IL-6 
levels of these samples were determined by enzyme-linked 
immunosorbent assay. 14 Moreover, CS-A difference of 
malondialdehyde 10 minutes after reperfusion and serum 
level of maximum creatine kinase MB for 24 hours after 
the operation were also measured and compared between 
the groups. 14 
In vitro experimental study. An in vitro experiment was 
carried out with cardiac myocytes and vascular endothelial 
cells from rats to examine whether IL-6 is produced by 
hypoxic myocytes and whether this enhances neutrophil 
transendothelial migration in association with myocyte 
damage. Myocytes and endothelial cells were isolated 
from the hearts of Wistar rats, weighing 150 to 200 g, by 
means of retrograde irrigation with collagenase and Per-- 
coll fractionation. Neutrophils were isolated from the 
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Table I. Clinical data in both groups 
Untreated group FUT-175-treated group P vahw 
Age 63 + 18 y 61 ± 16 y NS 
No. of grafts 2.8 + 0.4 2.6 -+ 0.6 NS 
Durat ion of AXC 95 -+ 45 rain 88 + 26 min NS 
Durat ion of CPB 132 + 36 rain 119 + 29 min NS 
CS-A of IL-6 before AXC 2 + 2 pg/ml 3 _+ 2 pg/ml NS 
After reperfusion 12 + 4 pg/ml 4 .+_ 3 pg/ml P = .04 
CS-A of MDA 2.1 + 0.4 nmol/ml 0.7 _+ 0.3 nmol/ml P = .04 
Max CK-MB 43 + 12 IU/L  15 _+_ 6 IU/L  P = .03 
AXC, Aortic crossclamp; CPB, cardiopulmonary b pass; CS-A, coronary sinus arterial difference; MDA, naalondialdehyde; CKMB, creatine kinase-MB. 
blood of the same rats with the use of Percoll fractionation 
as described before. 9
An in vitro experimental model as shown in Fig. 1, 
across which neutrophils can migrate, was composed of a 
uniform upper chamber of endothelial cells and a lower 
chamber of myocardial cells in a modified Boyden cham- 
ber. A collagen membrane served as a border between the 
2 layers. 9 By means of this model, only isolated cardiac 
myocytes in the lower chamber were exposed to 2 hours of 
hypoxia (2H) which can cause severe reversible damage to 
myocardial cells) ~ After reoxygenation f these myocytes, 
a monolayer of endothelial cells in the upper chamber was 
combined with that in the lower chamber. Subsequently, 
neutrophils, labeled with a nonspccific fluorescent dye 
(PKH2), were applied to the upper chamber (endothelial 
cells) of the model, and the fluorescence intensity of the 
neutrophils that had penetrated into the lower layer 
(myocardial cells) was measured with a fluorescent spec- 
troscope FR1500 (Shimadzu, Kyoto, Japan) 1 hour after 
reoxygenation. The proportion of the fluorescence of the 
neutrophils that had migrated into the lower chamber 
relative to that of all neutrophils applied was considered 
as the neutrophil migration rate. At the same time, the 
fluorescence intensity of neutrophils adhering directly to 
the myocytes was measured and the proportion relative to 
the total fluorescence intensity of all neutrophils applied 
was regarded as the neutrophil adherence rate. Moreover, 
the proportion of injured myocytes was also measured, by 
means of trypan blue staining, and the 10-minute cumu- 
lative chemiluminescence, g nerated by injured myocytcs, 
was measured with a Luminometer device (Nichinonn, 
Tokyo, Japan). 
These coincubation models were divided into 3 groups: 
group N (normoxia), group 2H (exposed to 2 hours of 
hypoxia), and group 2H with monoclonal antibody anti- 
I L-6, which was exposed to hypoxia and administered 
anti-lL-6 monoclonal antibody (Genzyme Corporation, 
Cambridge, Mass) during hypoxia. Hypoxia was induced 
by consumption of oxygen in a closed gas pack system 
(Becton Dickinson & Co, Rutherford, NJ) with palladium 
as a catalyst. Hypoxia was continued for 2 hours, the 
hypoxic level being monitored with methylene blue. 
IL-6 levels in the supernatant of cultured myocytes or 
endothelial cells after 2 hours of hypoxia were measured 
by enzyme-linked immunosorbent assay. 15 FUT-175 (× 10 
nmol/L) was administered to myocytes during hypoxia to 
assess whether protease may play a role in the production 
of IL-6 from myocytes. 
Values of each parameter were expressed as mean ± 
standard eviation. The significance of differences within 
the same group was tested with the use of the paired t test. 
The unpaired t test was used to test the significance of 
differences between any two groups. Analysis of variance 
and subsequent post hoc test were used to test the 
significance of diffcrences among 3 or more groups. 
Results 
Clinical study 
[1,-6 production from human myocardium. In the 
control group, myocardial IL-6 production, as deter- 
mined by the difference between the IL-6 level in the 
arterial blood in the CPB circuit and its level in 
coronary venous blood, increased significantly (P - 
.04) after reperfusion (postreperfusion, 12 ± 4 
pg/mL) as compared with that before aortic cross- 
clamping (before crossclamping, 2 _+ 2 pg/mL). 
In the FUT-475-treated group, the increase in the 
IL-6 level was suppressed significantly (before cross- 
clamping, 3 _+ 2; after reperfusion, 4 _+ 3). Thus IL-6 
production differed significantly between the control 
group and the FUT-175-treated group (P = .04, 
Table I, Fig. 2). 
Myocardial damage cot:elated with IL-6. In the 
FUT-175-treated group, the CS-A difference of 
malondialdehyde was suppressed significantly less 
than in the control group (FUT, 0.7 + 0.3; control, 
2.1 +_ 0.4, P = .04). Maximum serum level of 
creatine kinase MB during 24 hours of postopera- 
tive course was significantly (P = .03) lower in the 
FUT-175-treated group (15 ± 6) than that in the 
control group (43 ± 12) (Table I). 
In vitro experiment 
Neutrophil migration. The neutrophil migration 
rate in group 2tt (78% ± 13%) was significantly 
higher than that in group N (26% ± 11%) (P = .04). 
The increase in this parameter after 2 hours of 
hypoxia was suppressed significantly by treatment 
with anti- IL-6 monoclonal antibody (42% ± 19%) 
(P - 0.04, Fig. 3). 
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Fig. 1. An in vitro experimental model for neutrophil migration. The model, across which neutrophils can 
migrate, is composed of a uniform upper layer of endothelial cells and a lower layer of myocytes in a 
modified Boyden chamber. A collagen membrane serves as a border between the two layers. 
Neutrophil adherence. The percentage of neutro- 
phils that adhered to myocytes after penetration 
across the endothelial cell layer was significantly 
higher in group 2H (64% + 21%) than in group N 
(22% + 12%) (P < .05). The increase in the 
neutrophil attachment rate after 2 hours of hypoxia 
was suppressed significantly by treatment with anti- 
IL-6 monoclonal antibody (32% + 19%) (P = .04, 
Fig. 4). 
Myocyte damage. The percentage of damaged 
myocytes, that is, cells positively stained by trypan 
blue, after 2 hours of hypoxia (48% +_ 17%) was 
significantly higher than that after normoxia (12% ± 
8%) (P = .04). The increase in this parameter after 
2 hours of hypoxia was suppressed significantly by 
treatment with anti-IL-6 monoclonal antibody (26% 
± 15%) (P = 0.04, Fig. 5, a). 
The chemiluminescence (X]03), determined si- 
multaneously as an indicator of oxygen-derived free 
radical production, was significantly higher after 2 
hours of hypoxia (22 _+ 8) than after normoxia (5 + 
2), but its increase after 2 hours of hypoxia was 
suppressed significantly by treatment with anti-IL-6 
antibody (7 _+ 3) (P = .04, Fig. 5, b). 
1L-6 production by myocytes and endothelial cells. 
The IL-6 production by endothelial cells of coronary 
vessels did not differ between group 2H (283 _+ 151) 
and group N (151 ± 86) (P = .06) (Fig. 6, a). The 
IL-6 level in the supernatant of cultured myocardial 
cells was significantly higher in group 2H (455 _+ 260 
pg/mL) than in group N (47 ± 15 pg/mL) (P = .04). 
FUT-175 treatment significantly suppressed IL-6 
production in myocardial cells (123 ± 24 pg/mL) as 
compared with that in group 2H (P = .04, Fig. 6, b). 
Discussion 
We previously reported findings suggesting the 
involvement of neutrophils in damage to ischemic 
myocytes, including findings that adhesion mole- 
cules are involved in the neutrophil migration into 
injured myocardium and that the recognition of 
injured areas of myocardium by circulating neutro- 
phils is promoted by a signaling factor produced by 
myocytes injured by ischemia. 9 Our clinical study, 
presented in this paper, has revealed that during 
cardiac operations on adult human beings, ischemia 
resulted in an increase in myocardial IL-6 produc- 
tion and this increase was suppressed by FUT-175, a 
serine protease inhibitor. Our in vitro study revealed 
that after 2 hours of hypoxia, the IL-6 production by 
myocytes increased significantly as compared with 
IL-6 production by endothelial cells, resulting in 
enhanced adhesion of neutrophils to the vascular 
endothelium. And neutrophil migration in associa- 
tion with myocyte damage observed in a co-culture 
system of myocytes and coronary vascular endothe- 
lial cells after 2 hours of hypoxia nd this neutrophil- 
mediated myocyte damage was suppressed by anti- 
IL-6 monoclonal antibody. These results indicate 
that myocytes produce cytokines uch as IL-6 when 
exposed to ischemia and that these cytokines are 
involved in the enhancement of neutrophil-medi- 
ated reperfusion i jury in myocardium. The pattern 
of mRNA for IL-6 in hypoxic neonatal rat myocytes 
has been reported 13 before, but there have been no 
prior reports dealing with direct production and the 
role of IL-6 by adult and/or human myocytes. 
The results of this study suggest that one possible 
role of a cytokine Whose production by myocytes i
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Fig. 2. IL-6 production after postischemic reperfusion 
during cardiac operations. Myocardial IL-6 production, as 
determined bythe difference between the IL-6 l vel in the 
extracorporeal circuit and its level in coronary venous 
blood, was increased significantly after the release of 
aortic occlusion in the untreated group. This increase was 
suppressed significantly i  he FUT-175-treated group. 
IL-6 production differed significantly between the two 
groups. AXC, Aortic crossclamping. 
enhanced uring ischemia, such as IL-6, is the 
enhancement of neutrophil-mediated reperfusion 
injury including neutrophil migration and neutro- 
phil adherence in association with myocyte damage. 
However, the enhancement of neutrophil migration 
seems to be multifactorial and is unlikely to be 
caused by IL-6 alone, considering that (1) cytokines 
form a network and are kept in balance with each 
otherlS, 16 and (2) no investigators have reported on 
intercellular dhesion molecule-1 expression i vas- 
cular endothelial cells induced irectly by IL-6. ~v It 
is therefore plausible to suggest from the results of 
this study that an increase in IL-6 stimulates the 
induction of some other chemotactic factor (eg, 
IL-8), eventually eading to enhancement of neutro- 
phil infiltration, ~s rather than attributing promotion 
of neutrophil migration after reperfusion to the 
direct action of IL-6.17 
The Baylor group reported that cardiac lymph, 
collected from the hearts of dogs after postischemic 
reperfusion, exerted a chemotactic effect, that this 
lymph contained significant amounts of IL-6, and 
that the adhesion of neutrophils to the vascular 
endothelium was suppressed by anti-IL-6 monoclo- 
nal antibody. 17 These findings are identical to those 
obtained in the present study. It seems likely that 
the chemotactic fa tors detected in vivo in cardiac 
lymph by the Baylor group t7 are identical to the 
factors produced irectly by ischemic ardiac myo- 
cytes in our study, and that these factors passed out 
100 
*: P=0.04  to others 
50 
0 N 2H 2H+anti IL6 
Fig. 3. Neutrophil migration. The neutrophil migration 
rate was significantly higher in group 2H (exposed to 
hypoxia for 2 hours) than in group N (normoxia). The 
increase in this parameter after 2 hours f hypoxia was 
suppressed significantly by treatment with anti-IL-6 
monoclonal ntibody. 
of the cells and into coronary veins, as reflected by 
the detection of IL-6 in coronary venous blood of 
patients undergoing cardiac operations in the 
present study. 
No detailed study has been carried out concerning 
the involvement of protease in IL-6 production. It 
has, however, been reported that protease is in- 
volved in the release of cytokines after their produc- 
tion in cytokine-producing cells} 9 This finding is 
endorsed by the finding from the present study in 
vivo and in vitro that IL-6 production was sup- 
pressed by a protease inhibitor. We previously re- 
ported the possibility that FUT-175 suppresses 
reperfusion injury of the myocardium, 14 probably 
because this protease inhibitor educed local cyto- 
kine production such as IL-6 production in myocar- 
dium. FUT-175 is a nonspecific serine protease 
inhibitor, and there is a complex mechanism of 
interactions that may take place upstream from IL-6 
production. Therefore it is difficult to prove the 
direct evidence of a protease-dependent pathway of 
IL-6 production by the present study. However, the 
present study in vivo and in vitro suggests that 
inflammatory response including a protease may 
mediate IL-6 production and further investigations 
are needed to clarify its mechanism. 
In the present study, anti-IL-6 monoclonal anti- 
body in the in vitro experimental study and FUT-175 
in the clinical study attenuated neutrophil-mediated 
reperfusion injury in myocardium. This suggested 
that inflammatory esponse including both protease 
and IL-6 related the neutrophil-mediated myocar- 
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Fig. 4. Neutrophil adherence. The percentage ofneutro- 
phils that adhered to myocytes after migration across a 
monolayer of endothelial cells was significantly higher in 
group 2H than in group N. The increase in this parameter 
after 2 hours of hypoxia was suppressed significantly by 
treatment with anti-IL-6 monoclonal ntibody. 
(a) Myocyte damage 
*; P=O.Q4 to others  
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Fig. 5. Percentage ofdamaged myocytes, a, The percent- 
age of damaged myocytes, that is, myocytes stained posi- 
tively by trypan blue, was significantly higher in group 2H 
than in group N. The increase in this parameter after 2 
hours of hypoxia was suppressed significantly by treatment 
with anti-IL-6 antibody, b, The chemiluminescence was 
also significantly higher in group 2H than in group N. Tile 
increase in this parameter after 2 hours of hypoxia was 
suppressed significantly by treatment with anti-IL-6 anti- 
body. 
dial injury. These findings from the present study 
and previous studies endorsed our hypothesis that 
IL-6, produced in ischemic ardiac myocytes, leads 
to enhancement of neutrophil-mediated r perfusion 
injury of the myocardium. 
The mechanisms of the neutrophil-mediated 
reperfusion injury resemble, at first glance, the 
mechanisms of host defense against foreign matter 
invasion by neutrophit migration n the presence of 
inflammation. 3 However, our findings suggest that 
(a) Endothelial cells 
P=O.06 
I 
400 
300 
200 
100 
0 
N 2H 
800 
600  
400  
200  
(b) Myocytes 
*P=O.04  
N 2H 2H 
+ 
FUT-175  
Fig. 6. IL-6 production by myocytes and endothelial cells. 
a, IL-6 production by coronary endothelial cells did not 
differ significantly between group 2H and group N. b, The 
IL-6 level in the supernatant of myocyte cultures was 
significantly higher in group 2H than in group N. IL-6 
production increased significantly with time. Treatment 
with FUT-175 significantly suppressed IL-6 production by 
myocytes. 
neutrophil migration into ischemic myocardium 
causes exacerbation of myocardial damage rather 
than repair. Measures to prevent neutrophil migra- 
tion, therefore, seem essential in achieving better 
protection of the myocardium. Development of a 
clinically applicable anti-IL-6 antibody, as well as 
anti-intercellular adhesion molecule-1 and anti- 
CD18 antibodies will therefore be useful in prevent- 
ing neutrophil-mediated reperfusion injury during 
active thrombolytic therapy for myocardial infarc- 
tion and during cardiac operations. Moreover, blood 
or coronary sinus IL-6 levels seem to be significant 
as indicators of ischemic injury and myocardial 
infarction. 
Conclusion 
1. During cardiac operations on adult human 
beings, myocardial IL-6 production increased signif- 
icantly after reperfusion, and this increase was sup- 
pressed by FUT-175, a protease inhibitor. 
2. When a coincubation ofmyocytes and endothelial 
cells was cultured in hypoxic conditions for 2 hours, 
neutrophil migration increased significantly, accompa- 
nied by a significant increase in the proportion of 
damaged myocytes. These changes were suppressed 
significantly by an anti-IL-6 monoclonal antibody. 
3. Exposure of myocytes to hypoxia for 2 hours 
resulted in a significant increase in IL-6 production 
as compared with hypoxic endothelial cells. This 
change was suppressed by a protease inhibitor. 
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These  results suggest that dur ing card iac  opera-  
t ions, IL -6  product ion  by myocard ium (especial ly 
myocytes)  increases in the presence of  ischemia and 
that the IL-6 thus produced  enhances  neutroph i l -  
med ia ted  reper fus ion  injury in myocard ium.  
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